Olema Pharmaceuticals, Inc. ( (OLMA) ) has released its Q3 earnings. Here is a breakdown of the information Olema Pharmaceuticals, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for breast cancer, with a lead product candidate, palazestrant (OP-1250), and a KAT6 inhibitor (OP-3136). In its latest earnings report for the quarter ended September 30, 2025, Olema Pharmaceuticals highlighted a significant decrease in cash and cash equivalents, from $139.5 million at the end of 2024 to $35.3 million. The company reported a net loss of $42.2 million for the quarter, compared to a net loss of $34.6 million in the same period last year, reflecting increased research and development expenses. Despite the financial challenges, Olema Pharmaceuticals continues to advance its clinical programs, supported by $329 million in cash, cash equivalents, and marketable securities, and a $22 million credit facility. Looking ahead, the management remains focused on progressing its pipeline and believes that its current financial resources will support operations for at least the next 12 months.